CD277 takes the lead in human γδ T-cell activation

Blood

Volumn 120, Issue 11, 2012, Pages 2159-2161

  Kabelitz, Dieter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BUTYROPHILIN 3; INTERLEUKIN 2; ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BIOTRANSFORMATION; BONE METASTASIS; COMPETITIVE INHIBITION; GAMMA DELTA T LYMPHOCYTE; GENE TRANSFER; HUMAN; LEUKEMIA CELL; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; NONHUMAN; NOTE; OSTEOPOROSIS; PARASITOSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION;

EID: 84866314320     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-442731     Document Type: Note

References (9)

1. Harly C, Guillaume Y, Nedellec S, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood. 2012;120(11):2269-2279.
2. Wrobel P, Shojaei H, Schittek B, et al. Lysis of a broad range of epithelial tumour cells by human gammadelta T cells: involvement ofNKG2Dligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol. 2007;66(2-3):320-328. (Pubitemid 47063194)
3. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, de Libero G. HumanTcell receptor gammadeltaTcells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163-168. (Pubitemid 36152311)
4. Gertner-Dardenne J, Castellano R, Mamessier E, et al. Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol. 2012;188(9):4701-4708.
5. Kabelitz D. Human gammadelta T lymphocytes for immunotherapeutic strategies against cancer. F1000 Med Rep. 2010;2.pii:45.
6. Ness-Schwickerath KJ, Morita CT. Regulation and function of IL-17A- and IL-22-producing gammadelta T cells. Cell Mol Life Sci. 2011;68(14):2371-2390.
7. Wilhelm M, Kunzmann V, Eckstein S, et al. gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-206. (Pubitemid 36759655)
8. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7457. (Pubitemid 47206575)
9. Mookerjee-Basu J, Vantourout P, Martinez LO, et al. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol. 2010;184(12):6920-6928.